Atrium Therapeutics, Inc. Common Stock RNA
$11.35
-20.01%
at last close
Market Cap$194.15 million
P/E Ratio—
Div Yield—
Volume1.72M
52-Week Range
$10.75$73.06
Analyst Ratings
- Consensus
- Moderate Buy — 7 Buy · 7 Hold · 0 Sell (14 analysts)
- Avg. Price Target
- $55.31 (+387.3% upside)
Key Stats
- Today's Range
- $10.75 – $14.19
- 50-Day Range
- $10.75 – $14.68
- 52-Week Range
- $10.75 – $73.06
- Volume
- 1.72 million shs
- Average Volume
- 198K shs
- Market Cap
- $194.15 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.90
- Price / Sales
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Related Stocks
Compare head-to-head: RNA vs LLY·RNA vs JNJ·RNA vs ABBV·RNA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.